dimecres, 20 de maig del 2015

Baxter looks to growth post-Baxalta spinout

Baxter International looks to sales and margin growth after it spins out its biopharmaceutical arm as Baxalta, likely augmented with acquisitions.

Baxter looks to growth post-Baxalta spinout

Baxter (NYSE:BAX) said it plans to boost its sales and margin growth after the planned July 1 spinout of its biopharmaceutical division as Baxalta.

read more



from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1F1xVdu

Cap comentari:

Publica un comentari a l'entrada